Moreover, the inhibition of mitochondria fission via Drp1, the blockage of the release of HMGB1 or the blockage of the HMGB1 receptor RAGE enhance the sensitivity of anti-cancer agents in CRC. The gene discussed is HMGB1; the disease is cancer.